Anatara Lifesciences (ASX:ANR) OCF Margin %: 0.00% (As of Dec. 2025)


What is Anatara Lifesciences OCF Margin %?

Anatara Lifesciences ASX:ANR OCF Margin % is 0.00% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 954 Biotechnology companies, Anatara Lifesciences ranks worse than 104821.7% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Anatara Lifesciences's Cash Flow from Operations for the six months ended in Dec. 2025 was A$0.28 Mil. Anatara Lifesciences's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Anatara Lifesciences's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Anatara Lifesciences's current OCF Yield % is -34.49%.

The historical rank and industry rank for Anatara Lifesciences's OCF Margin % or its related term are showing as below:


During the past 11 years, the highest OCF Margin % of Anatara Lifesciences was -12.26%. The lowest was -51600.00%. And the median was -630.01%.

ASX:ANR's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Anatara Lifesciences OCF Margin % Related Terms

Anatara Lifesciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Anatara Lifesciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anatara Lifesciences OCF Margin % Chart

Anatara Lifesciences Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anatara Lifesciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anatara Lifesciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Anatara Lifesciences's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-2.272/0
= %

Anatara Lifesciences's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0.282/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Anatara Lifesciences (ASX:ANR) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Anatara Lifesciences and its competitors. According to the industry distribution chart, Anatara Lifesciences ranks #999999 out of 954 companies in the Biotechnology industry.
Is Anatara Lifesciences' OCF Margin % too high?
Anatara Lifesciences' current OCF Margin % is 0.00%. Based on the distribution chart, Anatara Lifesciences ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Anatara Lifesciences' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anatara Lifesciences ranks #999999 out of 954 companies for OCF Margin %. This places Anatara Lifesciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Anatara Lifesciences and its competitors. Anatara Lifesciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatara Lifesciences stock overvalued right now?
Anatara Lifesciences (ASX:ANR) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Anatara Lifesciences (ASX:ANR), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anatara Lifesciences Business Description

Address c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.